Clinical Trials Logo

Filter by:
NCT ID: NCT05942573 Recruiting - Clinical trials for Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Start date: December 24, 2022
Phase: Phase 2
Study type: Interventional

This study is conducted in patients with advanced metastatic gastric cancer including gastroesophageal junction cancer(patients with HER2 negative and PD-L1 CPS≥5).Patiens will recevie Serplulimab plus chemotherapy ((oxaliplatin+capecitabine) as first-line treatment. After PD,patients will randomly 2:1 assigned to treatment:one group will receive Serpluimab with Paclitaxel,Apatinib;another group will receive Paclitaxel with or without Ramucirumab.All of eligible patients will receive study drug treatment until loss of clinical benefit, unacceptable toxicity, death, withdrawal of informed consent

NCT ID: NCT05942521 Recruiting - Clinical trials for Alcohol Use Disorder

Effects of Subconscious Memory Extinction in Patients With Alcohol Dependence and Its Mechanism

Start date: July 20, 2023
Phase: N/A
Study type: Interventional

In this study, the subconscious memory extinction therapy based on very brief exposure is used to intervene to reduce the alcohol craving of alcohol-dependent patients, prevent relapse, and observe the psychological craving, heart rate, skin conductance, and pupil diameter changes of the patients during the brief exposure extinction. The main questions it aims to answer are: 1. Whether subconscious extinction intervention would reduce psychological craving and alcohol relapse? 2. What is the mechanism of subconscious extinction intervention in alcohol dependence?

NCT ID: NCT05942508 Recruiting - Clinical trials for Limited Stage Small Cell Lung Cancer

A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy

Start date: May 30, 2023
Phase: Phase 1
Study type: Interventional

To assess the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell lung cancer who do not progress after first-line chemoradiotherapy. Based on the incidence and severity of benign and serious adverse events, as well as abnormal laboratory

NCT ID: NCT05942456 Recruiting - Osteosarcoma Clinical Trials

Soluble B7-H3 as a Biomarker for Osteosarcoma

Start date: June 5, 2023
Phase:
Study type: Observational

Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.

NCT ID: NCT05942430 Recruiting - Clinical trials for Articular Cartilage Defect

Autologous Costal Osteochondral Transplantation for Talar Osteochondral Lesions

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effectiveness and safety of autologous costal osteochondral transplantation in the treatment of Hepple Stage V talar osteochondral lesions, compared with autologous osteoperiosteal transplantation. The main question it aims to answer is: • Whether autologous costal osteochondral transplantation can achieve better clinical outcomes and cartilage repair quality with lower donor site morbidity than autologous osteoperiosteal transplantation in the treatment of Hepple Stage V talar osteochondral lesions. Participants will be randomly assigned to the intervention group (undergoing autologous costal osteochondral transplantation) or the control group (undergoing autologous osteoperiosteal transplantation). Both groups of participants will receive the same postoperative rehabilitation process and follow-up evaluation.

NCT ID: NCT05942352 Recruiting - Alcohol Abuse Clinical Trials

Clinical Study of Ligustrazine in Treating Alcohol Addiction

Start date: July 28, 2023
Phase: Phase 4
Study type: Interventional

Alcohol consumption is one of the most important risk factors for chronic non-communicable diseases in the population, and it is also the main cause of death from cancer, cardiovascular disease and lung disease, causing serious health, economic and social problems. The current alcohol-abstinence drugs have limited therapeutic effects and still present a high relapse rate. It is an urgent need to develop effective drugs for the treatment of alcohol addiction. The multimodal mechanism of action of ligustrazine in the central nervous system indicates that ligustrazine is expected to be developed as a potential therapeutic drug for alcohol addiction. Our study investigated the therapeutic effect of ligustrazine on subjects with alcohol addiction and the mechanism of multimodal brain imaging by administering ligustrazine, in order to develop new targeted drugs for alcohol treatment and provide more effective diagnosis and treatment methods for clinical treatment.

NCT ID: NCT05942001 Recruiting - Clinical trials for Advanced Prostate Cancer

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Start date: September 15, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.

NCT ID: NCT05941936 Recruiting - Solid Tumor Clinical Trials

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

Start date: May 19, 2023
Phase: Early Phase 1
Study type: Interventional

This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients . The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and IL-2 therapy.

NCT ID: NCT05941741 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Start date: January 10, 2024
Phase: Phase 3
Study type: Interventional

This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.

NCT ID: NCT05941585 Recruiting - Clinical trials for Acute Myeloid Leukemia

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Start date: August 8, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the safety, efficacy and pharmacokinetics of mitoxantrone hydrochloride liposome injection combined with chemotherapy in previously untreated de novo acute myeloid leukemia.